Biocon Ltd says the US Food and Drug Administration (FDA) has approved Pebrilzo (pertuzumab-qcay) injection, a biosimilar to Perjeta used to treat HER2-positive breast cancer. Pebrilzo is a monoclonal antibody that blocks HER2 receptors on cancer cells. Biocon adds that the approval brings its tally to five oncology biosimilar therapies authorized in the United States.
The company also points to a global settlement and licensing agreement with Genentech, which it says enables the earliest permitted US launch window in the third quarter of calendar year 2028. Both outlets note that Pebrilzo previously received a positive opinion from the European Medicines Agency’s CHMP in September, recommending marketing authorization in Europe under the brand name Pebrilzo.
In framing, the two sources largely rely on Biocon’s regulatory filing and company statements, with both emphasizing the FDA nod, the drug’s role in HER2-positive breast cancer, and the expected timing of the US launch. The Economic Times and Free Press Journal present the same core details, with the rest of their context centered on Biocon’s existing portfolio and the European development update.